SAN RAFAEL, Calif.,
Feb. 18, 2021 /PRNewswire/
-- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader
in providing therapies for rare genetic diseases, today announced
the appointment of former Goldman Sachs partner and executive in
the life sciences industry, Maykin Ho, Ph.D., to its Board of
Directors.
"We are thrilled to welcome Maykin to BioMarin's Board of
Directors. She brings a breadth and depth of experience in
the healthcare industry and finance to an already exceptional
board," said Jean-Jacques Bienaimé, Chairman and Chief Executive
Officer at BioMarin. "Maykin brings an important perspective
to support BioMarin's growth trajectory as we strive to address the
unmet medical needs of people affected by rare genetic diseases and
deliver scientific breakthroughs."
"It is an honor to join the Board of Directors of BioMarin, a
leader in the development, manufacturing and commercialization of
first-in-class or best-in-class therapies for rare genetic
diseases," said Dr. Ho. "I look forward to working with the
Board and the management team to continue advancing the standard of
care for patients with these diseases."
About Dr. Ho
Dr. Maykin Ho has more than 30 years of experience in the
healthcare and finance industries. She serves on the boards of
Agios Pharmaceuticals Inc., FibroGen Inc., Grail Inc., Parexel, the
Aaron Diamond AIDS Research Center, and the Institute for Protein
Innovation. Dr. Ho is also a venture partner of Qiming Venture
Partners and a member of the Biotech Advisory Panel of the Stock
Exchange of Hong Kong. She is a
retired partner of the Goldman Sachs Group where she served as
senior biotechnology analyst, co-head of global healthcare
investment research, and advisory director for healthcare
investment banking. Prior to Goldman Sachs, Dr. Ho held various
managerial positions in licensing, strategic planning, marketing
and research at DuPont-Merck Pharmaceuticals and DuPont de Nemours
& Company. She was a postdoctoral fellow at Harvard Medical School and a graduate of the
Advanced Management Program at The Fuqua School of Business,
Duke University. Dr. Ho received a
Ph.D. in Microbiology and Immunology and a B.S. from the
State University of New York, Downstate
Medical Center.
About BioMarin
BioMarin is a global biotechnology company that develops and
commercializes innovative therapies for people with serious and
life-threatening rare disorders. The company's portfolio consists
of six commercialized products and multiple clinical and
pre-clinical product candidates.
For additional information, please visit www.BioMarin.com.
Information on BioMarin's website is not incorporated by reference
into this press release.
BioMarin® is a registered trademark of BioMarin Pharmaceutical
Inc.
Contacts:
|
|
|
|
Investors
|
Media
|
Traci
McCarty
|
Debra
Charlesworth
|
BioMarin
Pharmaceutical Inc.
|
BioMarin
Pharmaceutical Inc.
|
(415)
455-7558
|
(415)
455-7451
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biomarin-appoints-former-goldman-sachs-partner-and-life-sciences-executive-maykin-ho-phd-to-board-of-directors-301231248.html
SOURCE BioMarin Pharmaceutical Inc.